Storys zum Thema Krankheit

Abcam

Abcam the most awarded company at 2022 industry awards

Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...

MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...

FDI World Dental Federation

2

FDI World Dental Federation asks how can industry drive innovation to improve oral health?

EcoCare

2

Exclusive Health & Safety Partner of the Munich Security Conference 2022: EcoCare commissioned to carry out daily COVID-19 tests on top politicians and diplomats

NanoPass Technologies LTD.

NanoPass's intradermal injection platform proven to sustain COVID-19 vaccine antibodies using 1/15 of the dose reports Chinese Institute of Medical Biology

Nes Ziona, Israel and Shanghai, China (ots/PRNewswire) - Intradermal COVID vaccination studies are emerging in a global effort to multiply available doses by harnessing skin immunity to reduce dosage required for effective vaccination. In a hallmark study published recently by IMB scientists[1], subjects were ...

HealthBiocare GmbH

Pioneering research for non-invasive detection of cancer

Vienna / Baar (ots) - Scientists from the Swiss-Austrian research group HealthBiocare GmbH and System Biologie AG, in collaboration with the University of Vienna, have found a new non-invasive approach for the detection of the nine most common types of cancer. Although cancer is a leading cause of death worldwide, there are still no clinically approved tests for broader cancer screening of the population. The earlier ...

Debiopharm International SA

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

Lausanne, Switzerland and Durban, South Africa (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate ...

Accord Healthcare

Accord's SONDELBAY ®▼ (teriparatide) is given Green Light by CHMP

Harrow, England (ots/PRNewswire) - Sondelbay – is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device - Accord's fourth biosimilar, joins the company's established portfolio across Europe, and marks its first branded product in a new Bone Health franchise representing another great milestone in Accord's growing ...

Micreos

Micreos appoints Joost Goderie as CFO and member of the Board of Directors

The Hague, The Netherlands (ots/PRNewswire) - Micreos announced that it has appointed Joost Goderie to the management board as Chief Financial Officer (CFO). Joost will be working closely together with the other members of the management team to help drive Micreos's growth and deliver its targeted antibacterial technology to the world. He will be responsible for ...

NanoPass; Emergex

NanoPass's intradermal delivery platform used in Emergex's next generation COVID-19 vaccination study

Nes Ziona, Israel (ots/PRNewswire) - Intradermal COVID-19 vaccination studies are emerging in a global effort to use available doses more effectively by harnessing skin immunity to reduce the dosage required for effective vaccination, as well as to improve the immunogenicity of weaker vaccines. Additionally, there ...

genOway

genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology

Lyon, France (ots/PRNewswire) - genOway, a world leader in the field of genetically modified innovative research models, announced today that it has granted a non-exclusive CRISPR/Cas9 license to the most important funding institution of biomedical academic research in the United Kingdom. In December 2018, genOway ...

News Direct

ALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS

Servier

Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

Paris (ots/PRNewswire) - - Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerated oncology strategy with the acquisition of ...

Schweizerischer Nationalfonds / Fonds national suisse

Animal experiments and 3R: Immune cells live in a complex world

Bern (ots) - Some research relies almost entirely on animal models. An example is the SNSF-funded project on virus surveillance in the mouse brain. "The immune system has a place where it is born, a place where it is educated and a place where it goes to work." Natalia Pikor, research group leader at St. Gallen cantonal hospital, is studying one of the most complicated systems in the bodies of vertebrate animals and ...

Schweizerischer Nationalfonds / Fonds national suisse

Animal experiments and 3R: mucous membrane as a model

Bern (ots) - In an SNSF-funded project, researchers are studying how bacteria infect the lungs. They are developing an alternative to animal testing that complements existing methods. When bacteria enter our lungs or live in our guts, they physically interact with our own cells that line the openings of our body like a protective layer. Some bacteria help us digest, others make us sick. Alexandre Persat from EPF Lausanne ...

Debiopharm International SA

DEBIOPHARM IINVESTS IN VERISIM LIFE’S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...

Schweizerischer Nationalfonds / Fonds national suisse

Animal experiments and 3R: Wound healing in mice and cell cultures

Bern (ots) - Research projects involving animal experiments employ a variety of methods. An SNSF-funded project on skin diseases, ulcers and cancer exemplifies this. Sabine Werner, professor of cell biology at ETH Zurich, studies how wounds heal. Knowledge of cell and tissue processes helps to better understand, diagnose and treat certain skin diseases. Here the focus is not primarily cuts and abrasions but rather wounds ...

Abcam; Alamar Biosciences

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

Fremont, Calif. and Cambridge, England (ots/PRNewswire) - Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of ...

Novaliq GmbH

Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease

Heidelberg, Germany and Cambridge, Mass (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug ...

Debiopharm International SA

DEBIOPHARM FURTHER EXPLORES THE POTENTIAL OF ITS POTENT, HIGHLY SELECTIVE WEE1 INHIBITOR DEBIO 0123 IN PHASE 1 CANCER STUDY

Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...

Novaliq GmbH

PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS

Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the ...

BenevolentAI

BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio

London (ots/PRNewswire) - - Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to ...

Schweizerischer Nationalfonds / Fonds national suisse

Wastewater provides new insight into Covid-19 dynamics

Bern (ots) - An interdisciplinary team funded by the Swiss National Science Foundation shows that the R number of coronavirus can be estimated quickly and cost-effectively from wastewater. Since the start of the coronavirus (Sars-Cov-2) pandemic, many public health measures have been decided based on its dynamic of spread, more precisely, on the reproductive number of the virus, known as the R number. This value indicates ...

Menarini Silicon Biosystems

Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting

Bologna, Italy and Huntingdon Valley, Pa. (ots/PRNewswire) - Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating ...